Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manuf ...

The lawsuit in question concerns the FDA’s decision to officially declare the shortages of Mounjaro and Zepbound, both forms of the GLP-1 drug tirzepatide, to be over in October.

emphasizing their benefits when used under prescription. The MHRA collaborates with social media platforms, law enforcement, and border officials to tackle illegal sellers of weight-loss drugs Get ...

Britons who have piled on extra pounds over the Christmas festivities are being warned not to buy weight-loss ... these pills without a healthcare professional’s advice and prescription could ...

Experts are urging anyone looking to shed a few pounds in the New Year to think twice before buying dangerous weight-loss ... drugs such as semaglutide should only be obtained with a prescription ...

The drug has garnered ... Mounjaro is a prescription-based injectable medication originally developed to treat type 2 diabetes. However, its ability to induce significant weight loss has made ...

Usually controlled with medical devices, the move presents Zepbound as the first prescription drug treating this issue. Eli Lilly has firmly established itself in the weight-loss industry with ...

Tesla chief Elon Musk dubbed himself “Ozempic Santa” in an X post on Christmas Day, marking the tech billionaire’s latest show of support for weight-loss drugs as he has pushed for making ...

Ozempic was first greenlit for diabetics in 2017 and was given FDA approval for weight loss in 2021 under the brand name Wegovy. The drugs are both injectable forms of semaglutide, a GLP-1 inhibitor.

Nearly half of US adults admit they’d take one of the newer, injectable weight loss ... 2021 to December 2023, of which 58.9% were female. The overall prevalence of discontinuation of GLP-1 ...